Roger Stupp, MD
Hematology & Oncology · Chicago, ILNPI 1295271088
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $96,198 of the $113,144 with a category attached, or 85.0%. 14 manufacturers reported payments, led by Novocure Inc. at 57.2% of the total. 2025 is the largest year on record at $75,551, 7.8 times the $9,673 reported in 2019. Among hematology & oncology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 43 payments — averaging $2631.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novocure Inc.$65K
- GT Medical Technologies, Inc$10K
- Siemens Medical Solutions USA, Inc.$8K
- Bristol Myers Squibb$8K
- Telix Pharmaceuticals$6K
- Ipsen Biopharmaceuticals, Inc$5K
- plus $12K from 8 others
Across 9 payments — averaging $60,877 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$303K
- Astrazeneca UK Limited$234K
- Lantheus Medical Imaging, Inc.$12K
What the payments were for
- Consulting fees$96,19885%
- Travel & lodging$14,89113%
- Food & beverage$2,0562%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novocure Inc. | 13 | $64,750 |
| GT Medical Technologies, Inc | 1 | $10,200 |
| Siemens Medical Solutions USA, Inc. | 5 | $8,428 |
| Bristol Myers Squibb | 1 | $7,840 |
| Telix Pharmaceuticals | 5 | $5,587 |
| Ipsen Biopharmaceuticals, Inc | 1 | $4,568 |
| Celularity Inc. | 2 | $3,600 |
| Insightec,inc | 1 | $3,000 |
| AstraZeneca | 2 | $2,439 |
| Bayer | 3 | $1,677 |
| Boston Scientific | 5 | $737 |
| Novocure GmbH | 2 | $161 |
| Monteris Medical Corporation | 1 | $125 |
| Stemline Therapeutics Inc. | 1 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Optune Gio$62,229
- GammaTile$10,200
- Exablate$3,000
- Optune$2,143
- Stivarga$1,588
- EMBOLD Fibered$444
- TheraSphere Y90 Glass Microspheres 10 GBq$128
- Neuroblate$125
How this compares
$113,144 in reported general payments places this provider in the 90th percentile of 580 hematology & oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Chicago
- Michael BishopChicago$974K
- Jamile ShammoChicago$910K
- Young Kwang ChaeChicago$563K
- Irfan MirzaChicago$544K
- Marina GarassinoChicago$397K
- Chih-Yi LiaoChicago$317K
- Rita NandaChicago$286K
- Shuo MaChicago$280K
- Santosh SarafChicago$275K
- Peter RiedellChicago$273K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.